Market Overview

UPDATE: Wunderlich Securities Initiates Coverage of Echo Therapeutics with Hold Rating, $1.75 PT

Related ECTE
Echo Therapeutics Gets Fresh Patent For Non-Invasive Sensing Technology
Echo Therapeutics Says It's In Final Stage Of Clinical Research Organization Selection
Premarket Gainers / Losers as of 9:15 am (Seeking Alpha)

In a report published Friday, Wunderlich Securities initiated coverage on Echo Therapeutics (NASDAQ: ECTE) with a Hold rating and a $1.75 price target.

Wunderlich noted, “ECTE is developing a promising transdermal continuous glucose monitoring (CGM) technology for the critical care, diabetes, and drug delivery markets. ECTE's technology is intriguing to us, given the importance of CGM for the in-hospital critical care market, and the potential for a non-invasive CGM for the diabetes market. That said, we are cautious on several fronts, including long clinical timelines and the high likelihood of significant dilution going forward. We believe ECTE is a story that bears watching, especially as the company approaches pivotal trials, but the likelihood of significant dilution leaves us neutral on the shares.”

Echo Therapeutics closed yesterday at $1.65.

Latest Ratings for ECTE

Nov 2013Feltl & Co.MaintainsBuy
Jun 2013LifeTech CapitalDowngradesStrong BuyNeutral
Apr 2013WunderlichSuspendsHold

View More Analyst Ratings for ECTE
View the Latest Analyst Ratings

Posted-In: Wunderlich SecuritiesAnalyst Color Initiation Analyst Ratings


Related Articles (ECTE)

View Comments and Join the Discussion!